{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:22Z","timestamp":1791896362301,"version":"4.3.4"},"reference-count":45,"publisher":"Harborside Press, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Metastatic sarcomatoid renal cell carcinoma (msRCC) is an aggressive disease typically associated with poor outcomes following VEGF-targeted therapies. This study evaluated in real-world outcomes in patients with msRCC based on whether they received treatment with immune checkpoint inhibitors (ICIs).\n                    <jats:bold>Methods:<\/jats:bold>\n                    We conducted a multi-institutional, retrospective study of patients who received systemic therapy for msRCC between July 2010 and June 2020. In total, 203 patients across 6 US academic centers were included. Patients were categorized into 2 groups based on whether they received ICIs: ICI+ (n=155) and ICI\u2212 (n=48). Overall survival (OS) was estimated using the Kaplan\u2013Meier method and measured from the initiation of frontline systemic therapy. Treatment responses were evaluated by investigators at participating centers.\n                    <jats:bold>Results:<\/jats:bold>\n                    After a median follow-up of 48.1 months, OS was significantly longer in the ICI+ group (median OS, 31.0 vs 7.6 months; hazard ratio [HR], 0.38; 95% CI, 0.26\u20130.56;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001). ICI+ status (HR, 0.38; 95% CI, 0.25\u20130.59;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), non\u2013clear cell or unclassified histology (HR, 2.99; 95% CI, 1.86\u20134.79;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001), and sarcomatoid component \u226525% (HR, 1.69; 95% CI, 1.11\u20132.59;\n                    <jats:italic>P=<\/jats:italic>\n                    .015) were independently predictive of OS. OS benefit in ICI+ group was maintained in the second line or later (median OS, 39.6 vs 7.6 months; HR, 0.32; 95% CI, 0.21\u20130.49;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001). Among patients with non\u2013clear cell or unclassified histology, the ICI+ group had longer OS (median, 18.1 vs 7.0 months; HR, 0.20; 95% CI, 0.09\u20130.44;\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001). Objective (39.4% vs 18.8%;\n                    <jats:italic>P<\/jats:italic>\n                    =.014) and complete (11.0% vs 4.2%;\n                    <jats:italic>P<\/jats:italic>\n                    =.258) response rates were higher in the ICI+ group.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    A potential benefit of ICI-based therapy is suggested in both clear cell and non\u2013clear cell msRCC. The benefit was observed in both the first-line setting and in second-line or later lines of therapy.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2026.7058","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:14Z","timestamp":1791895394000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study"],"prefix":"10.6004","author":[{"given":"Dharmesh","family":"Gopalakrishnan","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"},{"name":"Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"},{"name":"Medical College of Wisconsin Cancer Center, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Collier","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Park","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center, Ann Arbor, MI"},{"name":"Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Zaemes","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabah","family":"Alaklabi","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen B.","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Tulane Cancer Center, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanquan","family":"Yang","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saby","family":"George","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Nat Rev Urol","first-page":"659","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum KA","year":"2020","unstructured":"Blum KA, Gupta S, Tickoo SK,  Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659\u2013678."},{"key":"B2","series-title":"Semin Diagn Pathol","first-page":"188","article-title":"Sarcomatoid lesions of the urogenital tract","volume":"10","author":"Reuter VE.","year":"1993","unstructured":"Reuter VE. Sarcomatoid lesions of the urogenital tract. Semin Diagn Pathol 1993;10:188\u2013201."},{"key":"B3","series-title":"Am J Surg Pathol","first-page":"435","article-title":"Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome","volume":"28","author":"Cheville JC","year":"2004","unstructured":"Cheville JC, Lohse CM, Zincke H,  Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004;28:435\u2013441."},{"key":"B4","series-title":"World J Oncol","first-page":"183","article-title":"Evolving paradigms in the management and outcomes of sarcomatoid renal cell carcinoma in the era of immune checkpoint inhibitors","volume":"11","author":"Aly R","year":"2020","unstructured":"Aly R, Aujla AS, Gupta S,  Evolving paradigms in the management and outcomes of sarcomatoid renal cell carcinoma in the era of immune checkpoint inhibitors. World J Oncol 2020;11:183\u2013187."},{"key":"B5","series-title":"Am J Surg Pathol","first-page":"1490","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt B","year":"2013","unstructured":"Delahunt B, Cheville JC, Martignoni G,  The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490\u20131504."},{"key":"B6","series-title":"Eur Urol","first-page":"93","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch H","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA,  The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2016;70:93\u2013105."},{"key":"B7","series-title":"World J Urol","first-page":"1913","article-title":"WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies","volume":"36","author":"Warren AY","year":"2018","unstructured":"Warren AY, Harrison D. WHO\/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 2018;36:1913\u20131926."},{"key":"B8","series-title":"Cancer Cell","first-page":"803","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer RJ","year":"2020","unstructured":"Motzer RJ, Banchereau R, Hamidi H,  Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 2020;38:803\u2013817.e4."},{"key":"B9","series-title":"Am J Surg Pathol","first-page":"275","article-title":"Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases","volume":"25","author":"de Peralta-Venturina M","year":"2001","unstructured":"de Peralta-Venturina M, Moch H, Amin M,  Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001;25:275\u2013284."},{"key":"B10","series-title":"Clin Genitourin Cancer","first-page":"e447","article-title":"Sarcomatoid renal cell carcinoma: population-based study of 879 patients","volume":"17","author":"Alevizakos M","year":"2019","unstructured":"Alevizakos M, Gaitanidis A, Nasioudis D,  Sarcomatoid renal cell carcinoma: population-based study of 879 patients. Clin Genitourin Cancer 2019;17:e447\u2013453."},{"key":"B11","series-title":"J Urol","first-page":"65","article-title":"Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma","volume":"167","author":"Mian BM","year":"2002","unstructured":"Mian BM, Bhadkamkar N, Slaton JW,  Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002;167:65\u201370."},{"key":"B12","series-title":"Clin Genitourin Cancer","first-page":"e79","article-title":"Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"13","author":"Kyriakopoulos CE","year":"2015","unstructured":"Kyriakopoulos CE, Chittoria N, Choueiri TK,  Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2015;13:e79\u201385."},{"key":"B13","series-title":"Front Oncol","first-page":"591001","article-title":"Prognostic significance of sarcomatoid differentiation in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"10","author":"Zhi H","year":"2020","unstructured":"Zhi H, Feng M, Liu S,  Prognostic significance of sarcomatoid differentiation in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Oncol 2020;10:591001."},{"key":"B14","series-title":"Med Oncol","first-page":"1530","article-title":"Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy","volume":"28","author":"Dutcher JP","year":"2011","unstructured":"Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011;28:1530\u20131533."},{"key":"B15","series-title":"J Urol","first-page":"959","article-title":"Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers","volume":"168","author":"Escudier B","year":"2002","unstructured":"Escudier B, Droz JP, Rolland F,  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 2002;168:959\u2013961."},{"key":"B16","series-title":"Med Oncol","first-page":"761","article-title":"A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802","volume":"29","author":"Haas NB","year":"2012","unstructured":"Haas NB, Lin X, Manola J,  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012;29:761\u2013767."},{"key":"B17","series-title":"Eur J Med Res","first-page":"287","article-title":"Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation","volume":"15","author":"Staehler M","year":"2010","unstructured":"Staehler M, Haseke N, Roosen A,  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2010;15:287\u2013291."},{"key":"B18","series-title":"Ann Oncol","first-page":"663","article-title":"Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies","volume":"25","author":"Voss MH","year":"2014","unstructured":"Voss MH, Bastos DA, Karlo CA,  Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol 2014;25:663\u2013668."},{"key":"B19","series-title":"Cancer","first-page":"3435","article-title":"Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma","volume":"121","author":"Michaelson MD","year":"2015","unstructured":"Michaelson MD, McKay RR, Werner L,  Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and\/or poor-risk metastatic renal cell carcinoma. Cancer 2015;121:3435\u20133443."},{"key":"B20","series-title":"Clin Genitourin Cancer","first-page":"e47","article-title":"Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma","volume":"16","author":"Maiti A","year":"2017","unstructured":"Maiti A, Nemati-Shafaee M, Msaouel P,  Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma. Clin Genitourin Cancer 2017;16:e47\u201357."},{"key":"B21","series-title":"Invest New Drugs","first-page":"1239","article-title":"A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component","volume":"37","author":"Park I","year":"2019","unstructured":"Park I, Lee HJ, Bae WK,  A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. Invest New Drugs 2019;37:1239\u20131246."},{"key":"B22","series-title":"Cancer Immunol Res","first-page":"1303","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph RW","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM,  PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res 2015;3:1303\u20131307."},{"key":"B23","series-title":"Cancer","first-page":"4823","article-title":"Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation","volume":"123","author":"Kawakami F","year":"2017","unstructured":"Kawakami F, Sircar K, Rodriguez-Canales J,  Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer 2017;123:4823\u20134831."},{"key":"B24","series-title":"Urol Oncol","first-page":"134.e9","article-title":"Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors","volume":"39","author":"Chahoud J","year":"2021","unstructured":"Chahoud J, Msaouel P, Ross JA,  Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 2021;39:134.e9\u201316."},{"key":"B25","series-title":"Oncoimmunology","first-page":"1606639","article-title":"Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors","volume":"8","author":"Hanif A","year":"2019","unstructured":"Hanif A, Pandey M, Khan S,  Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology 2019;8:1606639."},{"key":"B26","series-title":"J Clin Oncol","first-page":"1020","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott DF","year":"2021","unstructured":"McDermott DF, Lee JL, Bjarnason GA,  Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021;39:1020\u20131028."},{"key":"B27","series-title":"J Clin Oncol","first-page":"1029","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott DF","year":"2021","unstructured":"McDermott DF, Lee JL, Ziobro M,  Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol 2021;39:1029\u20131039."},{"key":"B28","series-title":"J Clin Oncol","first-page":"63","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor BA","year":"2020","unstructured":"McGregor BA, McKay RR, Braun DA,  Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features. J Clin Oncol 2020;38:63\u201370."},{"key":"B29","series-title":"Cancer Treat Res Commun","first-page":"100251","article-title":"Immunotherapy in metastatic sarcomatoid renal cell carcinoma: a single institution experience","volume":"25","author":"Park JJ","year":"2020","unstructured":"Park JJ, Kellezi O, Hamasha R,  Immunotherapy in metastatic sarcomatoid renal cell carcinoma: a single institution experience. Cancer Treat Res Commun 2020;25:100251."},{"key":"B30","series-title":"Clin Cancer Res","first-page":"78","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir NM","year":"2021","unstructured":"Tannir NM, Signoretti S, Choueiri TK,  Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res 2021;27:78\u201386."},{"key":"B31","series-title":"Eur Urol","first-page":"659","article-title":"Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial","volume":"79","author":"Rini BI","year":"2021","unstructured":"Rini BI, Motzer RJ, Powles T,  Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial. Eur Urol 2021;79:659\u2013662."},{"key":"B32","series-title":"ESMO Open","first-page":"100101","article-title":"Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial","volume":"6","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Larkin J, Pal S,  Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open 2021;6:100101."},{"key":"B33","series-title":"J Clin Oncol","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"37(Suppl)","author":"Rini BI","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V,  Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 2019;37(Suppl):Abstract 4500."},{"key":"B34","series-title":"Eur Urol Focus","first-page":"421","article-title":"Biological and clinical insight into the prevention and management of metastatic renal cell carcinoma with a sarcomatoid component","volume":"11","author":"Salgia NJ","year":"2025","unstructured":"Salgia NJ, Fujiwara Y, Xu B,  Biological and clinical insight into the prevention and management of metastatic renal cell carcinoma with a sarcomatoid component. Eur Urol Focus 2025;11:421\u2013424."},{"key":"B35","series-title":"JCO Oncol Pract","first-page":"Op2500278","article-title":"Postimmunotherapy and vascular endothelial growth factor inhibitor landscape in advanced renal cell carcinoma: treatment patterns, costs, and outcomes","author":"Shah NJ","year":"2025","unstructured":"Shah NJ, Shinde R, Bhattacharya R,  Postimmunotherapy and vascular endothelial growth factor inhibitor landscape in advanced renal cell carcinoma: treatment patterns, costs, and outcomes. JCO Oncol Pract 2025:Op2500278."},{"key":"B36","series-title":"Cancers (Basel)","first-page":"1434","article-title":"Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies","volume":"17","author":"Shah NJ","year":"2025","unstructured":"Shah NJ, Sura S, Shinde R,  Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies. Cancers (Basel) 2025;17:1434."},{"key":"B37","series-title":"J Clin Oncol","first-page":"4519","article-title":"Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and\/or rhabdoid (S\/R) metastatic non-clear cell renal cell carcinoma (nccRCC): results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","volume":"41(Suppl)","author":"Labaki C","year":"2023","unstructured":"Labaki C, Bakouny Z, Lemelin A,  Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and\/or rhabdoid (S\/R) metastatic non-clear cell renal cell carcinoma (nccRCC): results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol 2023;41(Suppl):Abstract 4519."},{"key":"B38","series-title":"N Engl J Med","first-page":"1655","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan RC","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA,  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655\u20131659."},{"key":"B39","series-title":"Lancet","first-page":"966","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch GH","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H,  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966\u2013970."},{"key":"B40","series-title":"Eur Urol","first-page":"111","article-title":"Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma","volume":"75","author":"Bhindi B","year":"2019","unstructured":"Bhindi B, Abel EJ, Albiges L,  Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75:111\u2013128."},{"key":"B41","series-title":"J Urol","first-page":"60","article-title":"The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy","volume":"185","author":"Choueiri TK","year":"2011","unstructured":"Choueiri TK, Xie W, Kollmannsberger C,  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60\u201366."},{"key":"B42","series-title":"N Engl J Med","first-page":"417","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"Mejean A","year":"2018","unstructured":"Mejean A, Ravaud A, Thezenas S,  Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417\u2013427."},{"key":"B43","series-title":"Eur Urol","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","author":"Mejean A","year":"2021","unstructured":"Mejean A, Ravaud A, Thezenas S,  Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80:417\u2013424."},{"key":"B44","series-title":"Front Oncol","first-page":"627025","article-title":"Dissecting outcomes: should cytoreductive nephrectomy be performed for patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation?","volume":"10","author":"Adashek JJ","year":"2020","unstructured":"Adashek JJ, Zhang Y, Skelton W,  Dissecting outcomes: should cytoreductive nephrectomy be performed for patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation? Front Oncol 2020;10:627025."},{"key":"B45","series-title":"Urology","first-page":"169","article-title":"The role of cytoreductive nephrectomy for sarcomatoid renal cell carcinoma: a 29-year institutional experience","volume":"136","author":"Silagy AW","year":"2020","unstructured":"Silagy AW, Mano R, Blum KA,  The role of cytoreductive nephrectomy for sarcomatoid renal cell carcinoma: a 29-year institutional experience. Urology 2020;136:169\u2013175."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7058\/article-10.6004-jnccn.2026.7058.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7058\/article-10.6004-jnccn.2026.7058.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:43:15Z","timestamp":1791895395000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/aop\/article-10.6004-jnccn.2026.7058\/article-10.6004-jnccn.2026.7058.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":45,"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7058","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}